期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性骨髓瘤患者血清IL-6的测定及其临床意义 被引量：1

暂未订购
导出
摘要 多发性骨髓瘤（MM）系浆细胞恶性肿瘤，是一种起源于B细胞系并能够产生单克隆免疫球蛋白的恶性增殖性疾病．以骨髓中大量克隆性浆细胞的增生和积聚并分泌单克隆免疫球蛋白（M蛋白）或其片段，同时伴有广泛的溶骨病变和（或）骨质疏松为特征。由于MM的病因尚不明确，目前研究发现MM的可能发病机制有以下5条。①遗传因素，包括染色体数目和结构的改变。②病毒因素，如EB病毒、人类疱疹病毒8。
作者 黄琴 张晓燕 王晓敏
机构地区 新疆维吾尔自治区人民医院血液科
出处 《诊断学理论与实践》 2010年第3期264-265,共2页 Journal of Diagnostics Concepts & Practice
关键词 多发性骨髓瘤 白细胞介素6 诊断
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1Fonseca R Barlogie B,Bataille R,et al.Genetics and cytogenetics of multiple myeloma:a workshop report[J].Cancer Res,2004,64(4):1546-1558.
  • 2Dong HY,Scadden DT,de I.eval L,et al.Plasmablastic lymphoma in HIV-positive patients:an aggressive EpsteinBarr virus-associated extramedullary plasmaeytic neoplasm[J].Am J Surg Pathol,2005,29(12):1633-1641.
  • 3王晖,刘心.多发性骨髓瘤的发病机制及药物治疗进展[J].国际病理科学与临床杂志,2006,26(5):403-406. 被引量：6
  • 4李勇华,侯健.多发性骨髓瘤的发病机制[J].中国全科医学,2007,10(18):1492-1495. 被引量：17
  • 5Hideshima T,Bergsagel PL,Kuehl WM,et al.Advances in biology of multiple myeloma:clinical applications[J].Blood,2004,104(3):607-618.
  • 6陶中飞,傅卫军,陈玉宝,袁振刚,王东星,侯健.206例多发性骨髓瘤预后因素分析及分期评价[J].癌症,2006,25(4):461-464. 被引量：45
  • 7Alexandrakis MG,Passam FH,Boula A,et al.Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothdial growth factor in multiple myeloma[J].Ann Hematol,2003,82(1):19-23.

二级参考文献30

  • 1张天弼,廖建军.多发性骨髓瘤117例分析[J].中国基层医药,2006,13(6):1018-1019. 被引量：5
  • 2Myeloma Trialists' Collaborative Group.Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma:an overview of 6,633 patients from 27randomized trials[J].J Clin Oncol,1998,16(12):3832-3842.
  • 3Clerc D,Fermand J P,Mariette X.Treatment of multiple myeloma[J].Joint Bone Spine,2003,70(3):175-186.
  • 4Turesson I,Abildgaard N,Ahlgren T,et al.Prognostic evaluation in multiple myeloma:an analysis of the impact of new prognostic factors[J].Br J Haematol,1999,106(4):1005-1012.
  • 5Bataille R,Boccadoro M,Klein B,et al.C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system[J].Blood,1992,80 (3):733-737.
  • 6Greipp P R,San Miguel J,Durie B G,et al.International staging system for multiple myeloma[J].J Clin Oncol,2005,23 (15):3412-3420.
  • 7Pruzanski W.Clinical manifestations of multiple myeloma:relation to class and type M component[J].Can Med Assoc J,1976,114(10):896-897.
  • 8Jacobson J L,Hussein M A,Barlogie B,et al.A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience[J].BrJ Haematol,2003,122(3):441-450.
  • 9Bataille R,Durie B G,Grenier J,et al.Prognostic factors and staging in multiple myeloma:a reappraisal[J].J Clin Oncol,1986,4(1):80-87.
  • 10Higgins MJ,Fonseca R.Genetics of multiple myeloma[J].Best Pract Res Clin Haematol,2005,18:525-536.

共引文献65

同被引文献14

  • 1Elfar M, Fouda M, Yahya R, et al. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma[J]. J Physiol Biochem, 2004, 60(4): 253-8.
  • 2Nacinovic-duletic A, Stifter S, Dvomik S, et al. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in. patients with diffuse large B-cell lymphoma[J]. Int Jnl Lab Hem, 2008, 30(2): 230-9.
  • 3Sana I, Christine M, Sylvie C, et al. Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival[J]. Ann Hematol, 2010, 89(1): 25-33.
  • 4Jaffy ES, Harris NL, Stein H, et al. World health organization classification of tumours pathology and genetics of tumours of haematopoietic and lymphoid tissues [M]. 4th Lyon: IARC Press: 2008:158-334.
  • 5Casasnovas R, Mounier N, Bric P, et al. Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Oroupe d'Etude des Lymphomes de l'Adulte[J]. Clin Oncol, 2007, 25(30): 1732-41.
  • 6Pedersen LM, Klausen TW, Davidsen UH, et al. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin' s lymphoma [J]. Ann Hematol, 2005, 84(11): 510-6.
  • 7Stefan H, Manuela G, Giuseppina M, et al. Clinical significance of Interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma[J]. Leukemia Res, 2009, 33(23): 1352-56.
  • 8Ewa B, Anna B, Elzbieta A, interleukin- 10, interleukin-12 therapy and probability of et al. Pre-treatment serum levels of and their ratio predict response to event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias[J]. Clin Biochem, 2009, 42(32): 1144-57.
  • 9Aydin F, Yilmaz M, Ozdemir F, et al. Correlation of serum IL-2, IL-6 and IL-10 levels with International prognostic index in patients with aggressive non-Hodgkin' s lymphoma [J]. Am Clin Onco, 2002, 25(4): 570-2.
  • 10Lech-Maranda E, Baseggio L, Bienvenu J, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma [J]. Blood, 2004, 103(41): 3529-34.

引证文献1

二级引证文献10

诊断学理论与实践
2010年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部